GVB has been acquired by 22nd Century Group (Nasdaq: XXII), Read the Press Release Here
What is Cannabicitran? A CBT Guide | GVB Biopharma

Cart (0 item)

What is Cannabicitran? A CBT Guide

Posted 2 months ago by GVB Biopharma
Scientifically Reviewed By
Alissa Daschbach
MA, BS, and MH Medical Anthropology and Chemistry
Read Bio
Updated on May 02, 2022

Reviewed by Alissa B Daschbach MA BS MH

Dubbed the plant of the “thousand and one molecules¹,” cannabis is always providing us with new opportunities for discovery. Though it isn’t the latest discovery in the world of cannabis, the potential uses of the rare cannabinoid, CBT, were lamentably unexplored until recently.

With the latest advancements in cannabis science, it’s becoming possible to imagine a world in which even the rarest cannabinoids are commonplace. In this guide, learn what CBT is, and find out why you should be keeping track of the rapid evolution of the CBT hemp industry.

What is the cannabinoid CBT?

Cannabicitran (CBT) is a rare—yet naturally occurring—hemp cannabinoid that was first discovered in 1974². CBN has been a primary target of research and development operations since 2019.³ In fact, industry leaders are currently in the early stages of developing a variety of CBT products that could revolutionize the hemp industry by reliably unlocking the unique benefits of this highly promising cannabinoid.

There are quite a few subtypes of CBT, and we’re still learning about all the different ways this cannabinoid might affect the human body. Like CBD and CBG, however, CBT appears to be non-intoxicating, and its potential benefits are significant enough to be worthy of growing attention from the international scientific community.

What kind of research is being done on CBT?

Research into CBT is highly limited at present. In 2011, Japanese researchers isolated a substance chemically identical to CBT from Chinese rhododendron, a plant extensively used in Traditional Chinese Medicine (TCM). It could be argued that TCM practitioners have been using CBT for centuries, lending legitimacy to modern CBT research.

Then, an exhaustive 2018 study published in Natural Product Communications⁵ provided more background regarding the origins of CBT in cannabis. An unstable cannabinoid easily altered by enzymatic reactions, cannabichromene (CBC) serves as the origin of CBT in cannabis, not CBGa, raising new questions regarding the metabolism of cannabis flower during maturation.

The scientific community is eagerly looking forward to the results of research into CBT. This rare cannabinoid’s unique benefits are just now being uncovered, and what we’ve learned so far has the potential to revolutionize the global cannabis industry.

Who is the target audience for CBT?

Right now, CBT most appeals to adventurous cannabinoid consumers who always want to try the next best thing. It is still somewhat of a scientific mystery how this cannabinoid affects the human body and mind at present, but fans of CBD and CBG are endlessly eager to try new, non-psychoactive cannabinoids that may impart unique benefits not offered by other hemp compounds.

What are the effects of CBT?

Based on limited anecdotal testimony, CBT appears to have non-intoxicating effects that largely resemble the effects offered by CBD, CBG, or any other hemp cannabinoid that doesn’t cause intoxication. As one of the most obscure and least-used hemp substances, there isn’t enough anecdotal evidence yet to draw any firm conclusions regarding how CBT will affect individuals on a case-by-case basis.

What are the benefits of CBT?

In the cannabis industry, CBT is already sometimes used as an anti-crystallization ingredient since it helps compounds like CBD resist reverting to their natural crystalline states. Chemically, CBT has the same relationship to CBD as CBD has to THC, making this hemp substance useful in identifying cannabinoids in a sample.

A 1984 study⁶ researched the impact of CBT on glaucoma, potentially making this cannabinoid a non-intoxicating cannabis option for glaucoma patients currently using THC. Given CBT’s unique process of development within the cannabis flower, we can expect to be surprised regarding what we learn about this cannabinoid’s unique benefits over the coming years.

CBT Cannabinoid Comparisons

To further elucidate the unique benefits of CBT, let’s compare it to a few other cannabinoids:


Chemically, CBT bears a close resemblance to CBD. The two cannabinoids also appear to have similar effects, making CBD and CBT an ideal pair especially given the boosting effect of CBD’s ongoing popularity.


As a fellow non-intoxicating cannabinoid, CBT and CBG (cannabigerol) are more similar than they are different. CBT is a few branches separated on the cannabinoid family tree, however, from CBG, the “parent molecule” from which all the most popular cannabis compounds spring.


Based on what little we know already, CBT and cannabicyclol (CBL) appear to be quite similar. They’re both derivatives of CBC, and they’re both non-intoxicating. While CBT emerges via enzymatic processes, however, CBL comes into existence when CBC oxidizes.


CBT and THC aren’t very similar. THC is one of the few cannabinoids to cause intoxicating effects, a trait CBT doesn’t appear to share. From a regulatory perspective, THC and CBT are also quite different since THC remains a Schedule I drug while CBT products are typically considered to be in the usually considered industrial hemp category of cannabis products.

Which cannabinoids compliment CBT products?

When CBT becomes available, it will initially be challenging for products containing this novel cannabinoid to gain traction unless they’re paired with a substance that people are already familiar with. To this end, we suggest combining CBT with either CBD or CBC: CBD to take the well-traveled route, CBC to approach from a more experimental perspective.


The gold standard of hemp cannabinoids, CBD is now as trusted as any over-the-counter medicine or natural remedy. As such, it’s the ideal cannabinoid to pair with CBT—especially since CBD and CBT appear to offer similar effects. It’s the most popular cannabinoid on the market, so CBD is available in the widest array of bulk ingredient types.


CBC is just as ideal of a match for CBT as CBD but for different reasons. CBD and CBT may be chemically interrelated, but the same can be said for CBT and CBC, and CBC offers the allure of a new cannabinoid that is nonetheless more familiar and approachable than CBT. Like CBT, CBC is non-intoxicating.

Best white label products to infuse with CBT

  1. When will bulk CBT products become available on the market? Three particular product types jump out as ideal matches for the unique benefits of CBT:

1. Wholesale CBT tinctures

Tinctures are the trusted standby of the hemp industry. Consumers are already used to taking tinctures, and they rely on this product type to deliver the benefits of any cannabinoid quickly and effectively.

Tinctures are easily formulable with a myriad of different botanical ingredients and oils. It’s easy to make a tincture into a unique “business card” consumers can use to identify your brand. What better way to make your brand noticeable than by incorporating a new, exciting cannabinoid!

2. Bulk CBT capsules

Since the dawn of the modern hemp industry, capsules have served as the default alternative for hemp consumers who don’t want to taste their cannabinoids on the way down. Bypassing the sublingual route and, therefore, not quite as bioavailable as tinctures, it’s nonetheless possible to formulate capsules with just as wide an array of ingredients with the added benefit of not needing flavoring. Capsules make CBT more approachable to consumers who are adventurous enough to try a new substance but want to avoid the inherent trickiness of tinctures.

3. White label CBT gummies

They aren’t quite as carb-free as capsules or tinctures, yet gummies are certainly the tastiest types of hemp products you can infuse with CBT or any other cannabinoid. Making daily dosing with cannabinoids easy and delicious, gummies are the most fun, approachable type of hemp product, countering hesitation consumers might experience when trying a new cannabinoid like CBT.

Preparing for the CBT wave

CBT is hardly the only cannabinoid waiting in the wings. Up until the last decade, research into cannabis was haphazard and mainly carried out by the same teams of isolated Japanese and Israeli researchers. Now that cannabis is increasingly legitimized around the globe, international cannabinoid research efforts have become more cohesive, and we’re starting to get some of the first definitive results regarding the cannabis plant and the hundreds of distinct compounds it contains.

Alongside CBT, related cannabinoids like CBC and CBL are also rising to the forefront of the hemp industry. If this all seems like too much for consumers to keep track of right now, think back to the status of CBD circa 2010. At that point, nobody could have predicted this then-obscure hemp compound would become a household name within less than a decade.

The consumer market simply needs time to adjust to new trends, and entrepreneurs have always benefited by preparing for these surges in sentiment before they make landfall. It’s never too early to start educating consumers regarding the oncoming CBT wave. By offering related cannabinoids like CBC that are already plentiful, you can give your customers a taste of the wider world of hemp that will open up the moment CBT products become available.


  1. 1. Andre, C. M., Hausman, J. F., & Guerriero, G. (2016). Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in Plant Science, 7. https://doi.org/10.3389/fpls.2016.00019
  2. 2. Bercht, C., Lousberg, R. J., Küppers, F. J., & Salemink, C. A. (1974). Cannabicitran: A new naturally occurring tetracyclic diether from lebanese Cannabis sativa. Phytochemistry, 13(3), 619–621. https://doi.org/10.1016/s0031-9422(00)91362-1
  3. 3. (2019, December 9). GVB Biopharma Begins Research on CBT (Cannabicitran), Unexplored Cannabinoid [Press release]. https://www.biospace.com/article/releases/gvb-biopharma-begins-research-on-cbt-cannabicitran-unexplored-cannabinoid/
  4. 4. Iwata, N., & Kitanaka, S. (2011). New Cannabinoid-Like Chromane and Chromene Derivatives from Rhododendron anthopogonoides. Chemical and Pharmaceutical Bulletin, 59(11), 1409–1412. https://doi.org/10.1248/cpb.59.1409
  5. 5. Pollastro, F., Caprioglio, D., del Prete, D., Rogati, F., Minassi, A., Taglialatela-Scafati, O., Munoz, E., & Appendino, G. (2018). Cannabichromene. Natural Product Communications, 13(9), 1934578X1801300. https://doi.org/10.1177/1934578×1801300922
  6. 6. Elsohly, M. A., Harland, E. C., Benigni, D. A., & Waller, C. W. (1984). Cannabinoids in glaucoma II: The effect of different cannabinoids on intraocular pressure of the rabbit. Current Eye Research, 3(6), 841–850. https://doi.org/10.3109/02713688409000797

Get in touch today

Ready to Build Your Brand?